phase 1_2_completion

AbbVie Inc — blinatumomab (Phase I/II Trial Completion)

April 30, 2026$ABBV blinatumomabupdated 2mo ago

community read0 votes

Therapy area: Oncology. Indication: Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

Data sources

globaldata

Found something off?

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?